Cellular Biomedicine Group Stock Price, News & Analysis (NASDAQ:CBMG)

$10.50 0.00 (0.00 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$10.50
Today's Range$10.50 - $10.70
52-Week Range$5.05 - $13.85
Volume11,545 shs
Average Volume33,729 shs
Market Capitalization$152.71 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59

About Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group logoCellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94%
Quick Ratio4.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$630,000.00
Price / Sales233.50
Cash FlowN/A
Price / CashN/A
Book Value$4.62 per share
Price / Book2.27

Profitability

Trailing EPS($1.72)
Net Income$-28,200,000.00
Net Margins-7,579.14%
Return on Equity-42.56%
Return on Assets-40.22%

Miscellaneous

Employees109
Outstanding Shares14,010,000

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How will Cellular Biomedicine Group's stock buyback program work?

Cellular Biomedicine Group announced that its Board of Directors has approved a share repurchase program on Sunday, June 4th 2017, which authorizes the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) announced its quarterly earnings results on Tuesday, March, 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.43). The biotechnology company had revenue of $0.06 million for the quarter. Cellular Biomedicine Group had a negative net margin of 7,579.14% and a negative return on equity of 42.56%. View Cellular Biomedicine Group's Earnings History.

Where is Cellular Biomedicine Group's stock going? Where will Cellular Biomedicine Group's stock price be in 2017?

1 brokers have issued 12-month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Cellular Biomedicine Group.

Who are some of Cellular Biomedicine Group's key competitors?

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:

  • Terry A. Belmont, Chairman of the Board (Age 69)
  • Bizuo Liu, Chief Executive Officer, Interim Chief Financial Officer, Secretary (Age 50)
  • Xia Meng, Chief Operating Officer
  • Yihong Yao Ph.D., Chief Scientific Officer
  • Richard L. Wang Ph.D., Chief Operation Officer
  • Zhou Hansheng, Director
  • Gerardus A. Hoogland, Director (Age 59)
  • Gang Jacky Ji, Director (Age 41)
  • Hansheng Zhou, Non-Executive Director
  • Chun Kwok Alan Au, Independent Director (Age 42)

Who owns Cellular Biomedicine Group stock?

Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include LMR Partners LLP (0.10%) and Zurcher Kantonalbank Zurich Cantonalbank (0.07%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan and Tony Liu. View Institutional Ownership Trends for Cellular Biomedicine Group.

Who sold Cellular Biomedicine Group stock? Who is selling Cellular Biomedicine Group stock?

Cellular Biomedicine Group's stock was sold by a variety of institutional investors in the last quarter, including LMR Partners LLP. View Insider Buying and Selling for Cellular Biomedicine Group.

Who bought Cellular Biomedicine Group stock? Who is buying Cellular Biomedicine Group stock?

Cellular Biomedicine Group's stock was acquired by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Cellular Biomedicine Group.

How do I buy Cellular Biomedicine Group stock?

Shares of Cellular Biomedicine Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of Cellular Biomedicine Group stock can currently be purchased for approximately $10.50.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $152.71 million and generates $630,000.00 in revenue each year. The biotechnology company earns $-28,200,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Cellular Biomedicine Group employs 109 workers across the globe.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (CBMG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellular Biomedicine Group (NASDAQ:CBMG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$18.00$18.00$18.00
Price Target Upside: 100.00% upside100.00% upside100.00% upside239.62% upside

Cellular Biomedicine Group (NASDAQ:CBMG) Consensus Price Target History

Price Target History for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ:CBMG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017Maxim GroupSet Price TargetBuy$18.00HighView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings History and Estimates Chart

Earnings by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ CBMG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2017Q4 2016($0.43)($0.43)$0.06 millionViewN/AView Earnings Details
8/9/2016Q216($0.52)$0.07 millionViewN/AView Earnings Details
3/14/2016Q415($0.42)($0.43)$1.50 million$0.62 millionViewN/AView Earnings Details
11/13/2015Q3($0.43)($0.44)$0.63 millionViewN/AView Earnings Details
8/14/2015Q215($0.37)($0.44)$0.66 millionViewN/AView Earnings Details
5/18/2015Q115($0.40)($0.39)$0.60 millionViewN/AView Earnings Details
3/31/2015($0.32)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 4.03%
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2017Tony LiuCEOBuy10,000$6.83$68,300.00View SEC Filing  
2/22/2016Andrew K ChanSVPSell1,307$18.22$23,813.54View SEC Filing  
2/17/2016Andrew K. ChanSVPSell1,516$17.76$26,924.16View SEC Filing  
1/21/2016Andrew K. ChanSVPSell2,812$12.90$36,274.80View SEC Filing  
12/21/2015Andrew K. ChanSVPSell12,812$21.94$281,095.28View SEC Filing  
11/23/2015Andrew K. ChanSVPSell5,332$20.64$110,052.48View SEC Filing  
10/21/2015Wei (William) CaoCEOSell20,000$19.59$391,800.00View SEC Filing  
10/20/2015Andrew K. ChanSVPSell5,215$20.20$105,343.00View SEC Filing  
9/21/2015Andrew K. ChanSVPSell27,927$20.80$580,881.60View SEC Filing  
12/23/2014Pak To LeungMajor ShareholderSell142,857$14.00$1,999,998.00View SEC Filing  
6/26/2014David BolocanDirectorBuy10,000$5.00$50,000.00View SEC Filing  
5/22/2014Tony LiuCFOBuy100,000$5.00$500,000.00View SEC Filing  
7/23/2013Keith WongDirectorSell320,050$0.13$41,606.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cellular Biomedicine Group (NASDAQ CBMG) News Headlines

Source:
DateHeadline
BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
www.reuters.com - November 11 at 11:52 AM
Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint LaboratoryCellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
finance.yahoo.com - November 7 at 7:56 PM
BRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processesBRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
www.reuters.com - November 6 at 6:11 PM
Cellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing systemCellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing system
seekingalpha.com - November 6 at 6:11 PM
Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing ProcessesThermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
finance.yahoo.com - November 6 at 6:11 PM
Contrasting Cellular Biomedicine Group (CBMG) and Its PeersContrasting Cellular Biomedicine Group (CBMG) and Its Peers
www.americanbankingnews.com - November 6 at 3:15 PM
Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in LondonCellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
finance.yahoo.com - October 31 at 6:09 PM
Cellular Biomedicine Group, Inc. (CBMG) Scheduled to Post Earnings on MondayCellular Biomedicine Group, Inc. (CBMG) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Relative Strength Alert For Cellular Biomedicine GroupRelative Strength Alert For Cellular Biomedicine Group
www.thestreet.com - October 24 at 7:14 PM
BioCryst Pharmaceuticals (BCRX) and Cellular Biomedicine Group (CBMG) Critical SurveyBioCryst Pharmaceuticals (BCRX) and Cellular Biomedicine Group (CBMG) Critical Survey
www.americanbankingnews.com - October 22 at 8:22 PM
Cellular Biomedicine Group (CBMG) & The Competition Head-To-Head AnalysisCellular Biomedicine Group (CBMG) & The Competition Head-To-Head Analysis
www.americanbankingnews.com - October 22 at 2:08 PM
Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical CenterCerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center
www.businesswire.com - October 19 at 10:31 PM
Cellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowCellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 30 at 1:05 PM
Cellular Biomedicine Group Plans Grand Opening of its New Shanghai FacilityCellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
finance.yahoo.com - September 22 at 10:19 AM
One Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG)One Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG)
finance.yahoo.com - September 20 at 5:45 PM
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare ConferenceCellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 5:43 PM
This Chinese CAR-T Play is Worth Checking OutThis Chinese CAR-T Play is Worth Checking Out
seekingalpha.com - September 7 at 10:05 PM
ETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:35 PM
Maxim Group Reiterates "$18.00" Price Target for Cellular Biomedicine Group, Inc. (CBMG)Maxim Group Reiterates "$18.00" Price Target for Cellular Biomedicine Group, Inc. (CBMG)
www.americanbankingnews.com - August 29 at 1:04 PM
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:03 PM
Streetwise Reports Examines One Regenerative Medicine Firm to Keep a Close Eye OnStreetwise Reports Examines One Regenerative Medicine Firm to 'Keep a Close Eye On'
finance.yahoo.com - August 18 at 5:06 PM
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Given a $18.00 Price Target at Maxim GroupCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Given a $18.00 Price Target at Maxim Group
www.americanbankingnews.com - August 9 at 6:46 PM
Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business HighlightsCellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights
finance.yahoo.com - August 8 at 4:43 PM
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Scheduled to Post Earnings on MondayCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
Cellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in JuneCellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June
www.americanbankingnews.com - July 16 at 7:06 AM
ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:59 PM
Cellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell ProductsCellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
www.streetinsider.com - June 26 at 9:53 PM
BRIEF-Cellular Biomedicine Group announces stock repurchase programBRIEF-Cellular Biomedicine Group announces stock repurchase program
www.reuters.com - June 1 at 9:43 PM
Cellular Biomedicine Group (CBMG) Announces $10M Buyback ProgramCellular Biomedicine Group (CBMG) Announces $10M Buyback Program
www.streetinsider.com - June 1 at 9:43 PM
Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20
www.nasdaq.com - May 19 at 8:52 AM
BRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trialBRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
www.reuters.com - May 15 at 3:53 PM
BRIEF-Cellular Biomedicine Q1 net loss per share $0.43BRIEF-Cellular Biomedicine Q1 net loss per share $0.43
www.reuters.com - May 8 at 9:06 PM
Cellular Biomedicine reports 1Q lossCellular Biomedicine reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
Is Cellular Biomedicine Group A Buy?Is Cellular Biomedicine Group A Buy?
seekingalpha.com - March 26 at 10:49 AM
BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
www.reuters.com - March 15 at 2:06 AM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual ReportCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 14 at 9:04 PM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual ReportCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 14 at 11:12 AM
Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational ProgressCellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress
us.rd.yahoo.com - March 14 at 11:12 AM
Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese MarketExclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market
www.benzinga.com - March 4 at 1:35 AM
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.
us.rd.yahoo.com - March 1 at 10:29 AM
Cellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor ConferenceCellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 15 at 2:52 AM
Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on FebruaryCellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February
www.nasdaq.com - February 8 at 3:18 AM
Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017
feeds.benzinga.com - February 7 at 9:19 AM
Cellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in ChinaCellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in China
www.streetinsider.com - January 9 at 10:21 PM
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in AdultCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult
www.nasdaq.com - January 9 at 10:21 PM
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in ChinaCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China
us.rd.yahoo.com - January 9 at 9:00 AM
8:00 am Cellular Biomedicine announces three-month interim safety data from Phase I Clinical Trial for AlloJoin off-the-shelf allogeneic stem cell therapy for knee osteoarthritis8:00 am Cellular Biomedicine announces three-month interim safety data from Phase I Clinical Trial for AlloJoin off-the-shelf allogeneic stem cell therapy for knee osteoarthritis
us.rd.yahoo.com - December 10 at 11:39 AM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD DisclosureCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - December 8 at 4:56 PM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 30 at 7:01 AM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StatementsCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements
biz.yahoo.com - November 15 at 10:44 AM

SEC Filings

Cellular Biomedicine Group (NASDAQ:CBMG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellular Biomedicine Group (NASDAQ:CBMG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellular Biomedicine Group (NASDAQ CBMG) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.